Raymond James reiterates Strong Buy on Palvella stock, $193 target
📌 Key Takeaways
- {"type":"skipped","reason":"older_than_3_days"}
📚 Related People & Topics
Raymond James Financial
American multinational independent investment bank and financial services company
Raymond James Financial, Inc. is an American multinational independent investment bank and financial services company providing financial services to individuals, corporations, and municipalities through its subsidiary companies that engage primarily in investment and financial planning, in addition...
Entity Intersection Graph
Connections for Raymond James Financial:
Mentioned Entities
Deep Analysis
Why It Matters
Palvella Therapeutics has seen a 346% surge in its stock price over the past year, and a Strong Buy rating from Raymond James with a $193 target underscores growing confidence in its Phase 3 trial results. The company’s potential approval of a novel treatment for microcystic lymphatic malformation could open a new market and drive further upside for investors.
Context & Background
- Phase 3 trial bar raised to a mean mLM-IGA score of at least +1.0, up from +0.5
- Stock has surged 346% in the last year to $85.66 with a market cap of $1.01 billion
- All covering analysts maintain a Strong Buy consensus with price targets ranging from $143 to $212
- Breakthrough Therapy Designation granted by the FDA for QTORIN rapamycin
- Upcoming March readout expected to provide data on efficacy and safety
What Happens Next
The March readout will be critical in confirming the efficacy of Palvella’s QTORIN therapy and could lead to FDA approval, potentially boosting the stock further. Investors will closely monitor secondary endpoints and imaging data to assess the likelihood of market uptake.
Frequently Asked Questions
The higher bar indicates a more stringent efficacy threshold, which, if met, strengthens the case for regulatory approval and physician adoption.
Positive results could lift the stock, while negative or inconclusive data might cause a decline.
Palvella is also advancing QTORIN for porokeratosis, with Phase 2 expected in the second half of 2026.